Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $221.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 37.41% from the company’s current price.

Several other research analysts have also recently issued reports on KRYS. Citigroup lifted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital reiterated a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research note on Thursday, December 12th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech has an average rating of “Buy” and an average price target of $206.67.

Krystal Biotech Stock Up 2.7 %

Krystal Biotech stock opened at $160.83 on Wednesday. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34. The company has a market capitalization of $4.63 billion, a P/E ratio of 90.86 and a beta of 0.80. The stock’s 50 day moving average is $180.46 and its 200 day moving average is $185.00.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.67) earnings per share. As a group, equities analysts expect that Krystal Biotech will post 2.97 EPS for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 14.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EFG Asset Management North America Corp. grew its position in shares of Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after acquiring an additional 60 shares during the period. Nisa Investment Advisors LLC grew its holdings in Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after purchasing an additional 94 shares during the period. Arizona State Retirement System increased its position in Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after buying an additional 108 shares in the last quarter. Fiera Capital Corp raised its stake in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after buying an additional 130 shares during the period. Finally, KBC Group NV lifted its position in shares of Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after buying an additional 132 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).